

ADVANCES IN
APPLIED MICROBIOLOGY

VOLUME 65



Advances in
**APPLIED
MICROBIOLOGY**

VOLUME **65**

Edited by

ALLEN I. LASKIN

Somerset, New Jersey, USA

SIMA SARIASLANI

Wilmington, Delaware, USA

GEOFFREY M. GADD

Dundee, Scotland, UK



ELSEVIER

AMSTERDAM • BOSTON • HEIDELBERG • LONDON
NEW YORK • OXFORD • PARIS • SAN DIEGO
SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO

Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier
525 B Street, Suite 1900, San Diego, CA 92101-4495, USA
30 Corporate Drive, Suite 400, Burlington, MA 01803, USA
32, Jamestown Road, London NW1 7BY, UK

First edition 2008

Copyright © 2008 Elsevier Inc. All rights reserved

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: permissions@elsevier.com. Alternatively you can submit your request online by visiting the Elsevier web site at <http://elsevier.com/locate/permissions>, and selecting, *Obtaining permission to use Elsevier material*

Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made

ISBN: 978-0-12-374429-6

ISSN: 0065-2164

For information on all Academic Press publications
visit our website at elsevierdirect.com

Printed and bound in USA

08 09 10 11 12 10 9 8 7 6 5 4 3 2 1

Working together to grow
libraries in developing countries

www.elsevier.com | www.bookaid.org | www.sabre.org

ELSEVIER

BOOK AID
International

Sabre Foundation

Advances in
**APPLIED
MICROBIOLOGY**

VOLUME **65**

CONTRIBUTORS

Stephen J. W. Busby

School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom.

Jennifer S. Cavet

Life Sciences, University of Manchester, Manchester, M13 9PT, United Kingdom.

Christopher Y. Choi

Department of Agricultural and Biosystems Engineering, University of Arizona, Tucson, Arizona 85721.

Nicholas Clipson

Environmental Microbiology Group, School of Biology and Environmental Science, University College Dublin, Ardmore House, Belfield, Dublin 4, Ireland.

David Corbett

Faculty of Life Sciences, University of Manchester, Manchester, UK.

Evelyn Doyle

Environmental Microbiology Group, School of Biology and Environmental Science, University College Dublin, Ardmore House, Belfield, Dublin 4, Ireland.

Cormac GM Gahan

Alimentary Pharmabiotic Centre, Department of Microbiology and School of Pharmacy, University College Cork, Cork, Ireland.

Charles P. Gerba

Department of Soil, Water and Environmental Science, University of Arizona, Tucson, Arizona 85721.

David C. Grainger

Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, UK.

Anne Marie Hickey

Environmental Microbiology Group, School of Biology and Environmental Science, University College Dublin, Ardmore House, Belfield, Dublin 4, Ireland.

Colin Hill

Department of Microbiology and Alimentary Pharmabiotic Centre,
University College Cork, Cork, Ireland.

Kimon A. G. Karatzas

Department of Microbiology, School of Natural Sciences, National
University of Ireland Galway, Galway, Ireland.

Donald Y. Kobayashi

Department of Plant Biology and Pathology, Rutgers University,
New Brunswick, New Jersey, 08902.

Chin Hong Ma

Division of Biological Sciences, University of California at San Diego,
La Jolla, California 92093-0116.

Lorraine Muckian

Environmental Microbiology Group, School of Biology and Environmental
Science, University College Dublin, Ardmore House, Belfield, Dublin 4,
Ireland.

Conor P. O'Byrne

Department of Microbiology, School of Natural Sciences, National
University of Ireland Galway, Galway, Ireland.

Deenah Osman

Life Sciences, University of Manchester, Manchester, United Kingdom.

Cynthia A. Pielach

Department of Plant Biology and Pathology, Rutgers University,
New Brunswick, New Jersey, 08902.

Mark R. Riley

Department of Agricultural and Biosystems Engineering, University of
Arizona, Tucson, Arizona 85721.

Daniel P. Roberts

Sustainable Agricultural Systems Laboratory, USDA-Agricultural
Research Service, Henry A. Wallace Beltsville Agricultural Research
Center, Beltsville, Maryland, 20705-2350.

Ian S. Roberts

Faculty of Life Sciences, University of Manchester, Manchester,
M13 9PT, UK.

Loren Rodgers

Division of Biological Sciences, University of California at San Diego,
La Jolla, California 92093-0116.

Sheila Ryan

Department of Microbiology, University College Cork, Cork, Ireland.

Milton H. Saier

Division of Biological Sciences, University of California at San Diego,
La Jolla, California 92093-0116.

Ryan G. Sinclair

Department of Soil, Water and Environmental Science, University of
Arizona, Tucson, Arizona 85721.

Dorjee G. Tamang

Division of Biological Sciences, University of California at San Diego,
La Jolla, California 92093-0116.

Ming Ren Yen

Division of Biological Sciences, University of California at San Diego,
La Jolla, California 92093-0116.

CONTENTS

Contributors

xi

1. Capsular Polysaccharides in *Escherichia coli*

David Corbett and Ian S. Roberts

I. Introduction	2
II. Functions of Bacterial Capsules	2
III. Capsular Polysaccharides in <i>E. coli</i>	3
IV. <i>E. coli</i> Group 1 Capsules	4
V. <i>E. coli</i> Group 4 Capsules	6
VI. <i>E. coli</i> Group 3 Capsules	7
VII. <i>E. coli</i> Group 2 capsules	7
A. Genetics and evolution of <i>E. coli</i> Group 2 capsules	8
B. Biosynthesis of <i>E. coli</i> Group 2 capsular polysaccharides	10
VIII. Export of <i>E. coli</i> Group 2 Polysaccharides	12
A. Group 2 capsular polysaccharide synthesis and export are linked	14
IX. Regulation of Capsule Expression in <i>E. coli</i>	16
A. Regulation of the <i>E. coli</i> K30 capsule and expression of colanic acid (Slime) in <i>E. coli</i> K-12 strains	16
B. Regulation of expression of Group 2 (K5) capsule gene clusters	18
X. Conclusions	20
References	21

2. Microbial PAH Degradation

Evelyn Doyle, Lorraine Muckian, Anne Marie Hickey, and Nicholas Clipson

I. Introduction	27
II. Polycyclic Aromatic Hydrocarbons (PAHs)	28
A. Toxicity	28
B. Sources of PAHs	33
C. Environmental contamination	33
III. Degradation of PAHs	34
A. Pure culture studies	35
B. Culture-independent analysis	38
C. Marker genes	45
IV. Bioremediation of PAH Contaminated Environments	50
A. Factors affecting bioremediation	51

V. Conclusions	53
References	54

3. Acid Stress Responses in *Listeria monocytogenes*

Sheila Ryan, Colin Hill, and Cormac G.M. Gahan

I. Introduction	68
II. Listeriosis	68
III. Acid Tolerance Response (ATR) and Cross Protection	69
IV. Acid Resistance and Listerial Survival in Foods	70
V. Acid Resistance and <i>L. monocytogenes</i> Pathogenesis	71
VI. Listerial Mechanisms of Acid Resistance	73
A. GAD system	73
B. Arginine and agmatine deiminase systems	76
C. F_0F_1 -ATPase	76
D. Macromolecular protection and repair	77
E. Cell membrane changes	78
F. Sigma B	79
G. LisRK two-component regulatory system	81
VII. Conclusion	82
References	82

4. Global Regulators of Transcription in *Escherichia coli*: Mechanisms of Action and Methods for Study

David C. Grainger and Stephen J. W. Busby

I. Introduction	94
A. An overview of the bacterial multi-subunit RNA polymerase	94
B. DNA recognition by RNA polymerase	94
II. Regulation by Transcription Factors	96
A. An overview of transcription regulators	96
B. Global transcription factors	96
III. Regulation of Transcription by Nucleoid-Associated Proteins	99
A. The nucleoid-associated proteins	99
B. Mechanisms of transcription regulation by Fis, H-NS, and IHF	99
IV. A Novel Method for Studying Transcription on a Global Scale	101
A. Overview of chromatin immunoprecipitation	101
B. Application of ChIP-chip to the study of sequence specific transcription factors	102
C. Application of ChIP-chip to the study of nucleoid-associated proteins	105
D. RNA polymerase-omics	106
E. Protocols for ChIP-chip experiments with <i>E. coli</i>	106
V. Concluding Remarks	110
References	110

5. The Role of Sigma B (σ^B) in the Stress Adaptations of *Listeria monocytogenes*: Overlaps Between Stress Adaptation and Virulence

Conor P. O'Byrne and Kimon A. G. Karatzas

I. <i>Listeria monocytogenes</i> : An Adaptable Pathogen	116
II. The Sigma Factors of <i>L. monocytogenes</i>	116
III. Sigma B (σ^B)	118
A. Complex protein-protein interactions control σ^B activity	118
B. Elucidation of the σ^B regulon by proteomics and transcriptomics	121
IV. A Central Role for σ^B in Adaptation to Stress	122
A. σ^B and osmoregulation	122
B. σ^B and acid resistance	124
C. σ^B is involved in cryotolerance	126
D. σ^B affects piezotolerance	126
E. Antimicrobial resistance and σ^B	127
F. The role of σ^B in resistance to bile	128
V. Does Competition between Sigma Factors Influence Growth Rate in <i>L. monocytogenes</i> ?	128
VI. Role of σ^B in Metabolism	129
VII. σ^B Plays Important Role in Virulence	130
A. PrfA and the intracellular stages of infection	130
B. Early and extracellular stages of infection	131
VIII. Conclusions	134
References	135

6. Protein Secretion and Membrane Insertion Systems in Bacteria and Eukaryotic Organelles

Milton H. Saier, Chin Hong Ma, Loren Rodgers, Dorjee G. Tamang, and Ming Ren Yen

I. Introduction: Transport Protein Classification	142
II. The Diversity of Protein Translocases in Bacteria and Eukaryotic Organelles	144
III. Complex Inner Membrane Secretory Systems in Bacteria	151
A. Type I (ABC-MFP-OMF-type) protein exporters (Fig. 6.1)	151
B. General secretory translocases (Sec systems; Fig. 6.2)	152
C. Type III flagellar and pathogenicity-related systems (Fig. 6.3)	154
D. Type IV conjugation- and virulence-related (IVSP) systems (Fig. 6.4)	157
E. The putative type VI symbiosis/virulence secretory systems (TC #9.A.34)	159
F. Twin arginine translocation (Tat) systems (Fig. 6.5)	160
IV. OMP Translocases of Gram-Negative Bacteria	162
A. The MTB (Fig. 6.6)	162
B. FUP systems	164

C. Autotransporter-1 (AT-1) systems	165
D. Autotransporter-2 (AT-2) systems	165
E. The Intimin/Invasin or Autotransporter-3 Systems	166
F. Two-partner secretion (TPS) systems	167
G. OMP insertion porins (OmpIP)	170
V. Protein Translocases of Eukaryotic Organelles	172
A. MPT complexes (TIM-TOM; TC #3.A.8; Fig. 6.7)	172
B. The CEPT complex (Tic-Toc; TC #3.A.9; Fig. 6.9)	176
VI. Comparisons and Overview	179
References	183

7. Metabolic Behavior of Bacterial Biological Control Agents in Soil and Plant Rhizospheres

Cynthia A. Pielach, Daniel P. Roberts, and Donald Y. Kobayashi

I. Introduction	199
II. Techniques for Studying the Metabolic Behavior of Bacterial Biological Control Agents	201
III. Impact of Soil Edaphic Factors and Indigenous Microbes on Introduced Microbes in the Soil Environment	202
IV. Plant Influences on Microbial Metabolism in the Soil Environment	204
V. Conclusion	210
References	210

8. Copper Homeostasis in Bacteria

Deenah Osman and Jennifer S. Cavet

I. Introduction	217
A. The properties of copper	217
B. Copper requiring proteins	218
C. Principles of copper homeostasis	219
II. Mechanisms of Copper Trafficking and Resistance	220
A. P_{1B} -type ATPases	222
B. Copper acquisition	223
C. Copper detoxification	225
D. Sensors of elevated copper levels	231
E. Copper-chaperones	233
III. Copper and Bacterial Pathogenicity	234
IV. Copper as a Biocide	237
V. Concluding Remarks	238
References	239

9. Pathogen Surveillance Through Monitoring of Sewer Systems

Ryan G. Sinclair, Christopher Y. Choi, Mark R. Riley, and
Charles P. Gerba

I. Introduction	250
A. Monitoring for human pathogens in sewage	250
II. Potential Biological Agents in Sewage	251
A. Human pathogens secreted in bodily fluids	252
B. Duration of release and concentration in bodily fluids and skin	254
III. Concentration of Biological Agents in Sewage	259
IV. Laboratory Methods and Detection	260
A. Detection of pathogens	260
B. Survival of pathogens in sewer systems	261
C. Lessons learned from poliovirus: Monitoring as an early warning system	262
D. Differentiation of vaccine and virulent strains	263
V. Conclusions: The Probability of Detection	264
References	266

<i>Index</i>	271
--------------	-----

<i>Contents of Previous Volumes</i>	279
-------------------------------------	-----

Color Plate Section

CHAPTER 1

Capsular Polysaccharides in *Escherichia coli*

David Corbett and Ian S. Roberts¹

Contents	I. Introduction	2
	II. Functions of Bacterial Capsules	2
	III. Capsular Polysaccharides in <i>E. coli</i>	3
	IV. <i>E. coli</i> Group 1 Capsules	4
	V. <i>E. coli</i> Group 4 Capsules	6
	VI. <i>E. coli</i> Group 3 Capsules	7
	VII. <i>E. coli</i> Group 2 capsules	7
	A. Genetics and evolution of <i>E. coli</i> Group 2 capsules	8
	B. Biosynthesis of <i>E. coli</i> Group 2 capsular polysaccharides	10
	VIII. Export of <i>E. coli</i> Group 2 Polysaccharides	12
	A. Group 2 capsular polysaccharide synthesis and export are linked	14
	IX. Regulation of Capsule Expression in <i>E. coli</i>	16
	A. Regulation of the <i>E. coli</i> K30 capsule and expression of colanic acid (Slime) in <i>E. coli</i> K-12 strains	16
	B. Regulation of expression of Group 2 (K5) capsule gene clusters	18
	X. Conclusions	20
	References	21

Faculty of Life Sciences, University of Manchester, Manchester, UK

¹ Corresponding author: Faculty of Life Sciences, University of Manchester, Manchester, M13 9PT, UK

Advances in Applied Microbiology, Volume 65
ISSN 0065-2164, DOI: 10.1016/S0065-2164(08)00601-1

© 2008 Elsevier Inc.
All rights reserved.

I. INTRODUCTION

The expression of extracellular polysaccharide (EPS) material is a common feature of many bacteria. This EPS coats the outside of the bacterial cell and as a consequence plays an intimate role in mediating interactions between the bacterium and its immediate environment. In certain cases the polysaccharide may be tightly associated with the cell surface forming a discrete structure termed a capsule, or it may be shed in the form of EPS or slime. A number of roles have been assigned to polysaccharide capsules and it is clear that in a variety of environments the expression of a capsule confers a selective advantage to the host. The major components of bacterial capsules are highly hydrated, high molecular weight acidic polysaccharides that confer upon bacteria an overall negative charge and hydrophilic properties. There is great structural diversity in capsular polysaccharides both between different bacterial species but also within the same bacterial species. This diversity is a consequence of not only differences in the repeat monosaccharide components but also differences in linkage between the different repeating monosaccharide units. The selective pressure that has driven this diversity is unclear as are the mechanisms by which it has been achieved. However, a consequence of this structural diversity is that there exists a library of diverse polysaccharide structures within the microbiome that may be exploited to engineer novel polysaccharide molecules with particular biochemical, pharmacological, or immunological properties.

II. FUNCTIONS OF BACTERIAL CAPSULES

A number of functions have been assigned to bacterial capsules in different bacteria including adhesion, transmission, resistance to innate host defenses, resistance to the host's adaptive immune response, and intracellular survival (Roberts, 1996). In certain cases it is possible to directly correlate the function of the bacterial capsule with the chemical structure of the capsular polysaccharide. For instance, the adhesion of Group A Streptococci to pharyngeal cells mediated via the interaction between the hyaluronic acid capsule and CD44, the hyaluronic acid binding protein (Cywes and Wessels, 2001). In the case of invasive pathogens an ability to survive innate host defenses is essential. It has been known for a long time that the expression of a polysaccharide capsule confers some measure of resistance to complement-mediated killing (Roberts, 1996) even though mechanistically the basis for this is not always clear. In the case of capsules that contain sialic acid, binding of factor H and the inhibition of the complement activation cascade can explain this resistance, but with

other capsules it may be due to steric effects and masking the cell surface from the membrane-attack complex. What is clear is that complement mediated resistance is likely to involve a number of cell surface structures which contribute to the overall effect (Burns and Hull, 1998, 1999). The ability of capsules to confer resistance to phagocytosis by polymorphonuclear (PMNL) cells has long been assigned to the negatively charged polysaccharide capsule and the repulsive effect on the negatively charged cell surface of the PMNL (Roberts, 1996). However, it is likely that poor opsonization with complement of encapsulated bacteria will also play a role in this protection (Roberts, 1996). The *Escherichia coli* K1 capsule is vital for intracellular survival and crossing the blood brain barrier (Kim *et al.*, 2003). Specifically, the K1 capsule moderates the maturation process of *E. coli* containing vacuoles inside endothelial cells preventing fusion with lysosomes (Kim *et al.*, 2003). As such, expression of the K1 capsule is critical to the pathology of the disease.

III. CAPSULAR POLYSACCHARIDES IN *E. coli*

E. coli is a facultatively anaerobic, Gram-negative bacillus that forms part of the commensal human bowel flora, but in the environment can be found in soil and water, usually as the result of fecal contamination. Although considered a commensal organism and widely used as a workhorse in molecular biology research, *E. coli* is capable of causing a range of diseases in humans and animals, including gastro-intestinal and urinary tract infections, meningitis, and septicemia. A common feature of *E. coli* isolates responsible for extraintestinal infections is the expression of a polysaccharide capsule or K antigen. The expression of certain K antigens is strongly associated with particular infections. For example, the K1 capsule is the most common capsule type found in isolates of *E. coli* causing neonatal meningitis and urinary tract infection. The K5 polysaccharide is associated both with urinary tract infection and sepsis, but not with meningitis. In both cases, these capsules are more often found associated with infection than in the normal intestinal flora of healthy individuals (Kaijser and Jodal, 1984).

There are more than 80 different K antigens in *E. coli*, and originally, they were divided into Groups I and II on the basis of serological, biosynthetic and genetic data (Jann and Jann, 1997). The system has since been restructured to take account solely of biochemical and genetic data, comprising four groups: Group 1 (Ia), Group 2 (II), Group 3 (III), and Group 4 (Ib) (Whitfield and Roberts, 1999). The following sections briefly consider the genetics, biosynthesis and evolution of the capsular polysaccharides of the related Groups 1 and 4, then Group 3, followed by a detailed analysis of the Group 2 capsular polysaccharides.

IV. *E. coli* GROUP 1 CAPSULES

Group 1 capsules, encoded by the *cps* locus located near *his*, are typified by *E. coli* K30, which is a polymer of galactose, mannose, and glucuronic acid. They are similar to those expressed by *Klebsiella* strains, although in *E. coli* the capsular polysaccharide is expressed in two forms. The first comprises one to several repeat units of the K polysaccharide linked to lipid A-core, and is termed K_{LPS} (Dodgson *et al.*, 1996). This is not synthesized by *Klebsiella* spp. (Whitfield and Roberts, 1999). Lipid A and core are two conserved constituent domains of LPS, the third being the highly variable O antigen. All three components are synthesized separately and ligated together later. Lipid A is formed from UDP-GlcNAc and fatty acids that are transferred to a Kdo disaccharide. The core is an oligosaccharide linker that is formed on lipid A by the sequential transfer of glucose, galactose, and GlcNAc from their nucleotide precursors. The second higher molecular weight polysaccharide forms the capsule proper. In each case the repeating unit of the polysaccharide is identical.

The Group 1 capsule biosynthetic locus is a 16 kb region of DNA encoding 12 ORFs located in the same region of DNA as the typical O antigen biosynthetic locus in *E. coli* K-12 and strains bearing capsules from Group 2, 3, or 4 (Drummelsmith and Whitfield, 1999; Rahn *et al.*, 1999). The Group 1 gene cluster is distinguished by the presence of an essential polymerization and translocation region dedicated to capsule expression (*wzi-wzc*) that is conserved between different strains of *E. coli* expressing Group 1 capsules and *K. pneumoniae* (Whitfield, 2006). Strains bearing Group 1 capsules are unable to co-express colanic acid, the first evidence for which emerged when it was found that multicopy RcsB in *E. coli* K30, K1, K5, and K-12 resulted in a mucoid phenotype at 37°C, but only in serotype K30 was mucoidy the result of serotype-specific capsular polysaccharide expression: in all of the other strains this was due to colanic acid expression (Drummelsmith and Whitfield, 1999; Keenleyside *et al.*, 1992). Unlike bacteria belonging to Groups 2, 3, and 4, the genes responsible for synthesis of this EPS have been lost from Group 1 strains, probably through extensive DNA re-arrangements involving replacement of the O-antigen synthesis region by a large segment of DNA laterally transferred from *K. pneumoniae* (Rahn *et al.*, 1999; Whitfield, 2006).

It is not known how Group 1 capsules are linked to the bacterial cell surface, but unlike K_{LPS} , it does not involve LPS (Whitfield, 2006). The repeat units of these capsules are formed on the cytoplasmic face of the bacterial inner membrane followed by export across the inner membrane and polymerization to form the capsular polysaccharide. The precursor monosaccharides are first synthesized by the appropriate enzymes (e.g., ManB and ManC are responsible for generating UDP-mannose).

The glycosyltransferase enzyme WbaP then transfers galactose from free UDP-galactose in the cytoplasm to undecaprenyl phosphate, a lipid carrier molecule (Drummelsmith and Whitfield, 1999; Roberts, 1996). A further glycosyl transferase, namely WbaZ, then completes the formation of the repeating unit backbone, $-2)-\alpha\text{-Man-(1-3)-}\beta\text{-Gal-(1-}$. A side-branch also exists, formed from repeating glucuronic acid and galactose residues by the glycosyltransferase WcaN, which is linked to the main polysaccharide chain by WcaO (Drummelsmith and Whitfield, 1999). The repeat units are flipped across the bacterial inner membrane by an unknown process involving Wzx before being attached to the reducing terminus of the nascent undecaprenyl phosphate-linked polysaccharide at its reducing terminus by Wzy on the periplasmic face of the inner membrane. The Wzy protein is believed to function as a polymerase, although this role has not been directly demonstrated (Whitfield, 2006). Mutations in Wzy abolish capsule expression and reduce the length of K_{LPS} to one repeat unit (Drummelsmith and Whitfield, 1999). At some point the length of the nascent polymer must trigger export, and either Wzy or WaaL may play a role in determining the chain length (Whitfield, 2006). Strains carrying mutations in *wzy* are acapsular and add only one repeat unit onto K_{LPS} (Drummelsmith and Whitfield, 1999). Polymerization is terminated for K_{LPS} by WaaL-mediated transfer of the polymer to lipid A-core.

Translocation of the finished polymer involves the products of the genes *wza*, *wzb*, and *wzc*, encoded within a polymerization and translocation locus located upstream of the serotype-specific biosynthetic loci. Wzi (formerly *orf3* or *orfX*) is not essential for capsule expression (Drummelsmith and Whitfield, 1999), but *wzi* mutants show a significant reduction in cell associated and cell-free polymer (Rahn *et al.*, 2003). Wza is a surface-exposed outer membrane lipoprotein that forms octameric structures in the outer membrane, the bulk of which are exposed in the periplasm, and is essential for surface presentation of capsule (Collins *et al.*, 2007; Dong *et al.*, 2006; Drummelsmith and Whitfield, 2000; Nesper *et al.*, 2003). It represents the outer membrane accessory (OMA) protein of Group 1 capsules. OMAs carry a conserved signal peptidase motif that, after cleavage, is modified at a conserved cysteine residue to yield a lipoprotein (Paulsen *et al.*, 1997). Failure to acetylate Wza results in a failure of capsule export and intracellular accumulation of capsule polymer (Nesper *et al.*, 2003). Wza is found associated with Wzc, interacting via their periplasmic domains (Collins *et al.*, 2007). Wza-Wzc interaction is believed to hold Wza in an open conformation conducive to capsule export, as the Wza octomer encloses a large central cavity with a 22Å pore (Collins *et al.*, 2007). However, in the absence of Wzc, the Wza ring is closed at both the periplasmic and external faces (Beis *et al.*, 2004; Dong *et al.*, 2006). Wzc is a tyrosine autokinase protein similar to the chain-length regulating protein Wzz found in strains from other capsule groups.